Last reviewed · How we verify

NCT00331058

Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects

Terminated Phase 1 Last updated 28 June 2017
What this trial tests

Phase 1 trial testing Bronchoscopsy in Asthma in 58 participants. Terminated before completion.

Timeline
18 February 2006
Primary endpoint
7 July 2011
7 July 2011

Quick facts

Lead sponsorGlaxoSmithKline
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment58
Start date18 February 2006
Primary completion7 July 2011
Estimated completion7 July 2011
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 45, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to compare the expression of key GSK drug targets across the 4 asthma phenotypes and healthy subjects and secondarily to evaluate changes in target expression in response to a 2-week course of corticosteroids across the 4 asthma phenotypes. Each asthmatic subject in this study will undergo two bronchoscopies. Each healthy subject will undergo one bronchoscopy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other GlaxoSmithKline trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00331058.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing